Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brief psychotic disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: Brief psychotic disorder. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-004893-84 Sponsor Protocol Number: CBD-P Start Date*: 2019-08-22
    Sponsor Name:Mental Health Center Glostrup
    Full Title: Cannabidiol for treatment of non-affective psychosis and cannabis use
    Medical condition: Non-affective psychosis and lifetime cannabis use
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10037234 Psychosis LLT
    21.1 100000004869 10070996 Cannabis use LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022184-35 Sponsor Protocol Number: ATLAS Start Date*: 2011-10-04
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: A pragmatic randomised double-blind trial of Antipsychotic Treatment of very LAte-onset Schizophrenia-like psychosis: The ATLAS Trial
    Medical condition: late-onset schizophrenia-like psychosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10037234 Psychosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001582-12 Sponsor Protocol Number: 4 Start Date*: 2023-03-01
    Sponsor Name:Consorcio Centro de Investigacion Biomedica en Red (CIBER)
    Full Title: Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode.
    Medical condition: First episode SZ-spectrum individuals
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000520-14 Sponsor Protocol Number: NL46653 Start Date*: 2014-07-31
    Sponsor Name:University Medical Center Utrecht
    Full Title: Prednisolone addition for atients with recent onset psychotic disorder: the role of immune-modulating strategies in the treatment of psychosis.
    Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003076-22 Sponsor Protocol Number: PSY-201401_ESPRIT Start Date*: 2016-07-07
    Sponsor Name:Central Institute of Mental Health Mannheim (ZI)
    Full Title: Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trial investigating the efficacy of Acetylcysteine (ACC) and Integrated Preventive Psychological Intervention (IPPI) in...
    Medical condition: Clinical High Risk state for developing a first psychotic episode
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    20.0 10037175 - Psychiatric disorders 10061920 Psychotic disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000709-36 Sponsor Protocol Number: 15/0947 Start Date*: 2016-11-23
    Sponsor Name:UCL
    Full Title: Research into Antipsychotic Discontinuation and Reduction (RADAR): A Randomised Controlled Trial
    Medical condition: Schizophrenia, delusional disorders, schizoaffective disorder, psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    20.0 10037175 - Psychiatric disorders 10012256 Delusional disorders HLT
    20.0 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    20.0 10037175 - Psychiatric disorders 10037234 Psychosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-000053-27 Sponsor Protocol Number: MELIA Start Date*: 2020-07-09
    Sponsor Name:UMC Utrecht
    Full Title: The MEtformin-LIfestyle in Antipsychotic users trial (MELIA): optimizing the use of metformin in the management of antipsychotic-induced weight gain.
    Medical condition: Antipsychotic-induced weight gain (AiWG)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016715-38 Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL Start Date*: 2010-02-08
    Sponsor Name:University of Copenhagen
    Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and...
    Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10032314 Other nonorganic psychoses LLT
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 10037175 - Psychiatric disorders 10004916 Bipolar affective disorder, depressed, severe degree, specified as with psychotic behavior LLT
    16.1 10037175 - Psychiatric disorders 10025460 Major depressive disorder, recurrent episode, severe degree, specified as with psychotic behaviour LLT
    16.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    16.1 10037175 - Psychiatric disorders 10025468 Major depressive disorder, single episode, severe degree, specified as with psychotic behavior LLT
    16.1 10037175 - Psychiatric disorders 10046122 Unspecified psychosis LLT
    16.1 10037175 - Psychiatric disorders 10026780 Manic psychosis LLT
    16.1 10037175 - Psychiatric disorders 10012255 Delusional disorder, unspecified type PT
    16.1 10037175 - Psychiatric disorders 10051988 Acute and transient psychotic disorder LLT
    16.1 10037175 - Psychiatric disorders 10004924 Bipolar affective disorder, manic, severe degree, specified as with psychotic behavior LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005004-13 Sponsor Protocol Number: NEURAPRO-E FINAL Protocol Start Date*: 2010-10-14
    Sponsor Name:Orygen Research Centre
    Full Title: Add-on Therapie mit Omega-3 Fettsäuren bei Jugendlichen mit hohem Risiko für Schizophrenie und andere psychotische Störungen: eine Multizentren- Replikationsstudie Omega-3 Fatty Acids for Symptomat...
    Medical condition: In view of recent data and after a careful review of potentially neuroprotective treatment options in early psychotic illness, we have decided to replicate the findings of a randomized controlled t...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000256-33 Sponsor Protocol Number: Ra-P-OCD-01 Start Date*: 2019-06-27
    Sponsor Name:Uppsala University Hospital
    Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement
    Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-006561-32 Sponsor Protocol Number: OxyCog-01 Start Date*: 2009-11-05
    Sponsor Name:LWL University Hospital Bochum
    Full Title: Effects of intranasal application of oxytocin on empathy and mentalising in patients with psychotic disorders and severe personality disorders
    Medical condition: Schizophrenia, bipolar disorder, major depression, personality disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010276-16 Sponsor Protocol Number: F1D-MC-HGMX Start Date*: 2009-11-19
    Sponsor Name:Eli Lilly
    Full Title: A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
    Medical condition: Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    13.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004504-35 Sponsor Protocol Number: RF-2010-2311148 Start Date*: 2013-02-26
    Sponsor Name:IRCCS CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI
    Full Title: The use of Oxytocin as adjunctive therapy for the treatment of schizophrenia: a randomized, double blind trial
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000415-25 Sponsor Protocol Number: NAS-S-01 Start Date*: 2013-11-07
    Sponsor Name:Clinirx Tangent Research
    Full Title: A randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Naproxen, Simvastatin and their combination, compared to placebo as add-on to anti-psychotics in the trea...
    Medical condition: schizophrenia and schizoaffective disorder.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    21.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005399-16 Sponsor Protocol Number: ROAC2014 Start Date*: 2014-08-05
    Sponsor Name:Dr. Benedicto Crespo. Servicio Psiquiatría. Hospital Universitario Marqués de Valdecilla/IDIVAL
    Full Title: Randomized, flexible-dose, open-label comparison to investigate the effectivenes of second generation antipsychotics in first episode psychosis patients.
    Medical condition: FIRST EPISODE DRUG-NAÏVE OF PSYCHOSIS (SCHIZOPHRENIA SPECTRUM DISORDERS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000163-32 Sponsor Protocol Number: NorPEPS Start Date*: 2017-06-29
    Sponsor Name:Helse-Bergen HF
    Full Title: The Norwegian Prednisolone in Early Psychosis Study - NorPEPS The role of immune-modulating strategies in the treatment of psychosis
    Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005138-21 Sponsor Protocol Number: TC-5619-23-CRD-003 Start Date*: 2012-04-03
    Sponsor Name:Targacept Inc.
    Full Title: A double-blind, placebo-controlled, multicenter, parallel group study to assess efficacy, safety and tolerability of TC-5619 as augmentation therapy to improve negative symptoms and cognition in ou...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001573-28 Sponsor Protocol Number: Uni-Koeln-320 Start Date*: 2007-11-26
    Sponsor Name:Universität zu Köln
    Full Title: Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.
    Medical condition: Persons at risk of being prodromally symptomatic of psychosis (PAR)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003503-39 Sponsor Protocol Number: ABR54654 Start Date*: 2016-07-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
    Medical condition: Individuals at Ultra High Risk for Psychosis
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) IT (Completed) ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-000757-36 Sponsor Protocol Number: ASA-CRP-01 Start Date*: 2014-10-07
    Sponsor Name:Clinirx Tangent Research
    Full Title: A randomized trial administering aspirin vs. placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder with high CRP levels
    Medical condition: schizophrenia and schizoaffective disorder.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    17.0 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 09:35:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA